Quest Diagnostics Inc. (DGX)
){kind=small}
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.35 per share. This compares to earnings of $2.23 per share a year ago.
Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings
DGX heads into Q4 earnings with expected revenue and EPS growth, DIS momentum, and benefits from Fresenius assets and consumer testing.
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics: A Continuing Bullish Case For A Leader Among Diagnostic Testing Brands
Quest Diagnostics gets reaffirmed as a buy for the 3rd time in a row. Key bullish drivers include organic growth, macro demand, strong profit margins among peers, and an investment-grade view from Fitch and S&P. The key peer in the US of Labcorp, it is also a proven dividend grower.
Quest Diagnostics Incorporated (DGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Quest Diagnostics Incorporated (DGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?
DGX banks on acquisitions, advanced diagnostics and cost discipline, even as debt levels and macro pressures pose risks.
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?
Here is how Quest Diagnostics (DGX) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
